Humanwell Healthcare (Group) Co.,Ltd. 600079.SS Stock

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia with artificial respiration; remifentanil hydrochloride for Injection for induction of general anesthesia; hydromorphone hydrochloride injection For patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injection for general anesthesia induction; mifepristone preparations for termination of pregnancy or clinical remedial measures used to prevent pregnancy; compound muniziqi granules used to regulate endocrine, enhance immune function, treat liver and gallbladder inflammation, skin diseases, eliminate toxins in the body, etc.; urokinase for Injection for thromboembolic disease; neomycin sulfate API related preparations are used for the prevention and treatment of intestinal diseases in animals, and also used for external prevention and treatment of human skin, eyes, nose, and ears; and progesterone API relevant preparations are used for reactive diagnosis of threatened abortion, habitual abortion, and other amenorrhea or the cause of amenorrhea, etc. It also provides nervous system drugs, steroid hormone drugs, and Uighur ethnic medicines, as well as anti-infection drugs, OTC medicines, and other products. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1993 and is based in Wuhan, China.